Screener
Amneal Pharmaceuticals, Inc. AMRX Acquisition and integration costs
Acquisition and integration costs at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationAcquisitionRelatedCosts.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Selling, general and administrative | 148,722 | 124,266 | 287,582 | 242,554 |
| Research and development | 39,017 | 47,964 | 77,400 | 88,004 |
| Intellectual property legal development expenses | 2,087 | 2,017 | 3,629 | 3,784 |
| Acquisition costs | 7,600 | — | 12,753 | — |
| Restructuring and other charges | 554 | 1,024 | 1,204 | 1,595 |
| Charges (credit) related to legal matters, net | 8,057 | (390) | 8,751 | (390) |
| Other operating income | (1,298) | — | (8,239) | (5,122) |
| Operating income | 129,769 | 111,372 | 271,541 | 211,719 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s acquisition and integration costs?
- Amneal Pharmaceuticals, Inc. (AMRX) reported acquisition and integration costs of $7.6M in Q2 2026.
- What does acquisition and integration costs mean?
- Transaction and integration costs from M&A activity
Ask your AI about Amneal Pharmaceuticals, Inc.'s acquisition and integration costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude